Iron every other day: encouraging results, but no proof of equivalence

Two strategies compared over 42 days

The study included 66 women aged 18 to 50 whose blood ferritin was below 30 ng/mL. Randomly assigned to two groups, they received supplementation for 42 days. The source material provides access only to the PubMed abstract, not the full text.

One group received micronized, dispersible ferric pyrophosphate providing 21 mg of elemental iron every 48 hours, alongside a daily gut microbiota modulator. The other received sucrosomial ferric pyrophosphate providing 30 mg of elemental iron per day. These amounts describe the trial and are not dosing recommendations.

The primary outcome was ferritin, an indicator of iron stores. The researchers also measured several blood parameters, including transferrin saturation and hemoglobin.

Improved stores, with no difference detected

Ferritin increased during follow-up in both groups, with no statistically significant difference between treatments. Several other markers of iron status changed in similar ways. Hemoglobin remained stable.

The abstract provides neither the absolute magnitude of ferritin gains nor confidence intervals for the differences between groups. The absence of a statistically significant difference is therefore not enough to establish that the two strategies are equivalent.

Both interventions were generally well tolerated, with digestive side effects described as mild and transient. Without detailed frequencies by group in the abstract, we cannot conclude that the alternate-day strategy was better tolerated.

Dosing frequency is not the only variable

The biological rationale centers on hepcidin, a hormone that regulates iron absorption. This regulation provides a reason to study less frequent dosing, but does not by itself prove its clinical superiority.

Crucially, this trial does not simply compare the same product taken daily or every 48 hours. The formulation, iron dose and addition of a microbiota modulator all differ at the same time. The results cannot be attributed to dosing intervals alone.

These data concern short-term blood markers in iron-deficient women. They do not demonstrate improved fatigue, effective treatment of anemia or a benefit in people without iron deficiency.

What we can take away

This trial supports further evaluation of lower-dose, less frequent strategies. On its own, it does not justify changing prescribed supplementation.